Evaluation of a novel antiplatelet agent for secondary prevention in @entity1 with a history of XXXX : design and rationale for the @entity556 -Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.

@entity57941 @entity1 @entity64 @entity556 @entity548 @entity731 @entity583 @entity3657 @entity1747 @entity715 @entity8781 @entity65 @entity385
BACKGROUND: @entity556 potently activates platelets via interaction with the @entity8781 . @entity57941 is a novel antiplatelet agent that selectively inhibits the cellular actions of @entity556 via antagonism of the @entity8781 . Because @entity57941 does not interfere with other pathways for hemostasis, it is possible that @entity57941 reduces @entity715 with less increase in @entity548 than do other potent antiplatelet agents. STUDY DESIGN: TRA 2 degrees P-TIMI 50 is a phase III, randomized, double-blind, placebo-controlled, multinational clinical trial designed to evaluate the efficacy and safety of @entity57941 during long-term treatment of @entity1 with established @entity731 receiving standard therapy (up to 27,000). Eligible @entity1 with a history of @entity583 , @entity385 , or @entity3657 are randomized 1:1 to @entity57941 2.5 mg daily or matched placebo until the end of study. Randomization is stratified by the qualifying disease and planned use of a @entity1747 . The primary end point is the composite of @entity65 , @entity583 , @entity64 , or urgent coronary revascularization. The major secondary end point is the composite of @entity65 , @entity583 , or @entity64 . The evaluation of long-term safety includes @entity548 defined by the GUSTO and TIMI criteria. Recruitment began in September 2007. The trial will continue until 2,279 primary end points and 1,400 secondary end points are recorded with expected completion in 36 to 44 months from first enrollment. CONCLUSIONS: TRA 2 degrees P-TIMI 50 is evaluating whether a new approach to platelet inhibition via interruption of @entity556 -mediated platelet activation reduces major cardiovascular events with a favorable safety profile in @entity1 with established @entity731 .
